Trabectedin Plus Olaparib Has Activity in Patients With Soft-Tissue Sarcoma

Cancer Discovery - United States
doi 10.1158/2159-8290.cd-rw2018-160
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors

Unknown

Publisher

American Association for Cancer Research (AACR)

Related search

Trabectedin in the Treatment of Patients With Soft Tissue Sarcoma

Nowotwory
Cancer ResearchOncology
2018English

BRCA1 Haplotype and Clinical Benefit of Trabectedin in Soft-Tissue Sarcoma Patients

British Journal of Cancer
Cancer ResearchOncology
2015English

Role of Trabectedin in the Treatment of Soft Tissue Sarcoma

OncoTargets and Therapy
OncologyPharmacology
2009English

The Value of Trabectedin in the Treatment of Soft Tissue Sarcoma

Therapeutics and Clinical Risk Management
2016English

Efficacy of Trabectedin in Advanced Soft Tissue Sarcoma: Beyond Lipo- And Leiomyosarcoma

Drug Design, Development and Therapy
Drug DiscoveryPharmacologyPharmaceutical Science
2015English

Trabectedin for Inoperable or Recurrent Soft Tissue Sarcoma in Adult Patients: A Retrospective Cohort Study

BMC Cancer
Cancer ResearchOncologyGenetics
2016English

Worse Survival in Elderly Patients With Extremity Soft-Tissue Sarcoma

Annals of Surgical Oncology
OncologySurgery
2016English

Staged Reconstruction Brachytherapy Has Lower Overall Cost in Recurrent Soft-Tissue Sarcoma

Journal of Contemporary Brachytherapy
Nuclear MedicineRadiologyImagingOncology
2017English

Immunotherapy in Soft-Tissue Sarcoma

Current Oncology
Oncology
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy